• Go to navigation
  • Go to content
Iressa.com

Astrazeneca Worldwide

  • AstraZeneca Websites
AstraZeneca

Main navigation

  • HOME
  • About IRESSA
  • IRESSA: The story so far
  • 1st line EGFR mutation-positive advanced NSCLC
  • The IPASS study
  • Identifying EGFR mutation positive patients for NSCLC
  • Product information
  • Latest IRESSA news
  • The INTEREST study
  • Contact Us

Iressa

IRESSA
Transforming the first-line treatment of  EGFR mutation-positive advanced NSCLC

Read More

  • IRESSA (gefitinib) as a first-line treatment for EGFR mutation-positive advanced NSCLC

    IRESSA is an oral monotherapy treatment which offers superior progression-free survival, better tolerability and quality of life compared with doublet chemotherapy (carboplatin/paclitaxel) as first-line treatment for EGFR mutation-positive advanced NSCLC.

    Read More

  • The IPASS study

    IPASS (IRESSA Pan-ASia Study) was an open label, randomised, parallel-group study that assessed the efficacy, safety and tolerability of IRESSA versus doublet chemotherapy (carboplatin/paclitaxel) as 1st line treatment in a clinically selected population of patients from Asia.

    Read More

  • Identifying EGFR mutation positive patients

    Epidermal growth factor receptor (EGFR) is a protein found in abnormally high levels on the surface of many types of cancer cells, particularly non-small cell lung cancer (NSCLC) cells. A patient‘s EGFR mutation status (positive or negative) can be confirmed via a diagnostic test using a sample of tumour tissue.

    Read More

In Europe, IRESSA (gefitinib) is indicated for the treatment of adults with locally advanced or metastatic NSCLC (non small cell lung treatment) with activating mutations of EGFR-TK across all lines of therapy. For the latest IRESSA country by country indication information, please view here.

Iressa Overview

  • About IRESSA

  • IRESSA: The story so far

  • IRESSA as a first line treatment for advanced NSCLC

  • The IPASS study

  • Identifying EGFR mutation positive patients for NSCLC

  • Product information

  • Latest IRESSA news

  • The INTEREST study

Legal notices

  • Terms of use
  • Privacy policy
  • © AstraZeneca 2012